Peptilogics: Building a Computational AI Platform to Enable Discovery by Design
Jonathan Steckbeck
Founder, President & CEO, Peptilogics
Peptilogics is a clinical-stage biotechnology platform company designing and developing novel peptide therapeutics. With its computational platform, Peptilogics is advancing peptide drug design to access new, previously unexplored chemical space, while ensuring biological viability and scalable manufacturing. The company is supported by investors including Presight Capital, Founders Fund, and Peter Thiel, who are known for their investments in transformative companies such as AbCellera (NASDAQ: ABCL), Compass Pathways (NASDAQ: CMPS), SpaceX, and Synthego. Jonathan Steckbeck’s talk will provide an overview of the company including its history in peptide design, initial indication (PJI) entering Phase 1b, and AI discovery platform. In addition, he will share information about the future direction of the organization.